• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » MassDevice podcast: BG Medicine CEO Dr. Pieter Muntendam

MassDevice podcast: BG Medicine CEO Dr. Pieter Muntendam

March 24, 2011 By Brad Perriello

When BG Medicine (NSDQ:BGMD) took itself public last month, three years after first announcing (then scuttling) its first initial public offering, investors seemed to like what they saw. Sure, the company cut its share price in half just ahead of the $7-per-share offering Feb. 11, but shares have averaged nearly $8.41 since then — a 20.1 percent increase.*

Investors must like what they know of Waltham, Mass.-based BG and its galectin-3 diagnostic test for heart failure. The test detects the galectin-3 protein, which president and CEO Dr. Pieter Muntendam says is both a biomarker and the cause of a form of heart failure in which the heart muscle gradually stiffens.

Read more of MassDevice.com’s coverage of BG Medicine

But when we sat down with Muntendam earlier in March, he told us that the company’s greatest innovation may not be its first diagnostic but its business model, which turns the traditional path for getting a test to market on its head.

BG Medicine CEO Dr. Pieter Muntendam

Muntendam

Instead of just running the clinical studies needed to validate the galectin-3 test and handing it off to one of the industry’s larger players to take it to market, BG took the test from the clinical stage, through 510(k) clearance from the FDA and CE Mark approval in the European Union, and on to the market. Muntendam said the key challenge was convincing the larger players — BG has deals with Abbott (NYSE:ABT), Siemens (NYSE:SI), Alere (NYSE:ALR) and BioMérieux (EPA:BIM) — that the model would work. They’d have to buy into the idea that developing a test for their high-throughput devices would be a money-maker.

"Probably the most significant re-engineering we did was the re-engineering of the business model. The old business model was, an academic center finds something, they go to an Abbott or a Siemens or whatever, and do an exclusive deal. So [the inventors] don’t develop it," he explained. "We said, ‘No, no, no, we’re turning this into a full product.’ Now I’ve paved the way for automated versions to follow."

Galectin-3 test

Galectin-3 test

Galectin-3 is just the beginning, Muntendam added. The company is working on a project to develop a test for the type "vulnerable plaque" he said is implicated in deadly first-time heart attacks, again with the help of deep-pocketed corporate partners — Astra Zeneca (NYSE:AZN), Takeda Pharmaceutical (PINK:TKPYY), Merck (NYSE:MRK), Philips (NYSE:PHG) and GE (NYSE:GE) — and with the Framingham Heart Study. He’s also got his sights set on multiple sclerosis, he said.

"The key thing for us is to finish galectin-3 and get it out there. We’ll do the same, I predict, for heart attacks, and do the next one," Muntendam said. "We can do this many, many times over. There are so many unmet needs left."

Click here to listen to the podcast for free. You can also download an MP3 of the interview by right-clicking.

*Correction, March 24, 2011: This article originally and erroneously stated that BG Medicine’s IPO débuted at $8.00 per share. Return to the corrected sentence.

Filed Under: Device Talks Podcasts, Diagnostics, News Well Tagged With: BG Medicine Inc., Cardiac Markers, MassDevice Q&A

In case you missed it

  • HistoSonics, GE Healthcare agree to integrate ultrasound into sonic beam liver therapy
  • Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
  • FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths
  • Boston Scientific’s Acurate Neo2 valve performs well in studies
  • MicroTransponder reports first commercial implantation of its stroke rehab neurostim system
  • Ambu replaces CEO with new leadership
  • Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
  • FDA clears Accelus’ Toro-L interbody fusion system
  • Teleflex’s UroLift cleared in China to treat BPH
  • Globus Medical announces first surgeries with Excelsius3D
  • Abbott reports positive data on heart valve therapies
  • OncoRes Medical raises another $12.5M
  • NeuroMetrix’s Quell neuromodulation device wins FDA de novo nod to treat fibromyalgia
  • Inogen appoints Agnes Lee as senior VP of investor relations, strategic planning
  • Google Health hires FDA’s chief digital health officer

RSS From Medical Design & Outsourcing

  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]
  • How Minnetronix Medical helped Lazurite with its wireless surgical camera
    Minnetronix Medical (St. Paul, Minnesota) has played an important development and manufacturing partner role with Lazurite’s wireless surgical camera system. It’s been nearly two months since Lazurite (formerly Indago) announced FDA 510(k) clearance of its ArthroFree system. ArthroFree combines proprietary low-heat, high-intensity Meridiem light engine technology with advanced camera, battery and wireless transmission technologies and… […]
  • Instron releases TrendTracker data analysis workflow platform
    Instron announced that it released the TrendTracker module in Bluehill Central for accelerating data analysis workflows. Norwood, Massachusetts-based Instron designed TrendTracker with an intuitive interface to improve the data analysis workflow of single or multi-location materials testing laboratories. According to a news release, the platform features quick searching and the ability to display and analyze… […]
  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push
    Henry Schein (Nasdaq:HSIC) today named Dirk Benson as VP and chief commercial officer of the medical device manufacturer and distributor’s North America Distribution Group (NADG). Melville, New York-based Henry Schein is the world’s largest provider of health care supplies and services for office-based dental and medical practitioners, and NADG is the company’s largest business group. The… […]

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS